DCCR drug

Class action lawsuit filed against $SLNO alleging failure to disclose fluid retention safety concerns in DCCR drug trials, harming investors who bought shares March-November 2025.

Soleno Therapeutics faces class action lawsuit over allegedly undisclosed fluid retention safety issues with DCCR drug candidate during March-November 2025 period.

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

Portnoy Law Firm launches class action against $SLNO for allegedly concealing safety issues with lead drug DCCR, citing 27% stock plunge following patient death disclosure.

Class action filed against $SLNO for allegedly failing to disclose safety concerns about DCCR drug. Stock fell sharply after August 2025 short report and September patient death disclosure.

Soleno Therapeutics faces class action lawsuit alleging failure to disclose material DCCR drug safety concerns, including excess fluid retention in clinical trials that reduced commercial viability.

Rosen Law Firm alerts $SLNO investors about class action lawsuit alleging false statements regarding DCCR drug safety. Lead plaintiff deadline: May 5, 2026.

Pomerantz LLP sues Soleno Therapeutics ($SLNO) over alleged securities fraud as stock plummets 39% following DCCR safety concerns and patient death disclosure. Lead Plaintiff deadline: May 5, 2026.

Class action lawsuit filed against $SLNO alleging fraud over PWS drug DCCR. Safety concerns, patient death, and commercial disruption emerged in 2025.

Class action lawsuit filed against $SLNO alleging failure to disclose safety concerns about DCCR drug candidate, including fluid retention issues in clinical trials.

Soleno Therapeutics faces class action lawsuit over alleged failure to disclose safety issues with drug DCCR, following 12-27% stock declines from August-September 2025 revelations.

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR safety concerns, patient death, and disappointing Q3 results that triggered sharp stock declines.

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR drug safety concerns, patient death, and disappointing Q3 results.

Soleno Therapeutics ($SLNO) faces securities fraud lawsuit over DCCR drug for Prader-Willi syndrome. Stock plunged following safety concerns, patient death, and weak Q3 results.

Soleno Therapeutics faces class action lawsuit alleging failure to disclose safety concerns about DCCR drug candidate from clinical trials.

Soleno Therapeutics faces class action lawsuit alleging material safety concerns about DCCR drug were hidden from investors. Lead plaintiff deadline is May 5, 2026.

Class action lawsuit filed against $SLNO alleging false statements about DCCR safety concerns and commercial viability for Prader-Willi syndrome treatment.